In terms of pipeline development, the company reported positive results from the China bridging study of KarXT for schizophrenia and promising Phase 1 data for ZL-1310 in small cell lung cancer. Zai ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.
The failure of emraclidine, which AbbVie obtained after acquiring Cerevel, may present a considerable advantage for rival BMS ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate ...
Neuland Labs share price surged after AbbVie’s emraclidine trial setback shifted focus to KarXT. As the exclusive Xanomaline ...
Pharmaceutical company AbbVie announced that an experimental schizophrenia drug that was key to its $8.7 billion acquisition ...
Bristol-Myers Squibb entered the schizophrenia treatment market through last year's acquisition of biopharma firm Karuna ...
BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...
The drug, previously called KarXT, is an oral medication for the treatment of schizophrenia in adults. Cobenfy introduces a fundamentally new approach to treating schizophrenia by selectively ...
Bank stocks largely boosted the Dow, as investors hope the sector could see weaker regulation in a second Trump ...